2024
Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents
Zeidan A, Zhao R, Pierre-Victor D, Wang Y, Tepsick J, Lan Z, Salimi T. Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents. Blood 2024, 144: 5189-5189. DOI: 10.1182/blood-2024-205495.Peer-Reviewed Original ResearchAML-free survivalTreated with hypomethylating agentsOral hypomethylating agentsHypomethylating agentsMyelodysplastic syndrome patientsMyelodysplastic syndromeDEC-CClinical characteristicsMDS diagnosisNext treatmentMonths median follow-upRisk of AML transformationHigh-risk myelodysplastic syndromeReal-world treatment outcomesTreatment of adult patientsHypomethylating agent treatmentKaplan-Meier survival analysis methodMedian Follow-UpCox regression analysisReal-world studyAML transformationHMA therapyOral decitabineECOG 0Electronic health record database
2023
Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes
Jann J, Hergott C, Winkler M, Liu Y, Braun B, Charles A, Copson K, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer E, Wadleigh M, Stone R, DeAngelo D, Garcia J, Haferlach T, Lindsley C, Luskin M, Stahl M, Tothova Z. Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes. Blood 2023, 142: 999. DOI: 10.1182/blood-2023-187519.Peer-Reviewed Original ResearchAcute myeloid leukemiaDana-Farber Cancer InstituteProgression free survivalMyelodysplasia related changesMyelodysplastic syndromeOverall survivalTP53 mutationsSTAG2 mutationsRAD21 mutationsMDS/myeloproliferative neoplasmPrognostic impactClinical outcomesDana-Farber Cancer Institute cohortPrognostic impact of TP53 mutationsFollow-upDe novo acute myeloid leukemiaImpact of TP53 mutationsAllogeneic stem cell transplantationCohesin mutationsSecondary acute myeloid leukemiaRisk of leukemic transformationSubtype of myelodysplastic syndromeAnalysis of overall survivalAssociated with myelodysplastic syndromeAML-free survival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply